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Abstract
Objective—To identify clinical characteristics and biochemical markers in first-trimester
samples that would possibly predict the subsequent development of preeclampsia.
Methods—We conducted a multicenter observational study in 2,434 low-risk nulliparous women
to identify biomarkers that possibly predict preeclampsia. Clinical history, complete blood count,
and biochemical markers were assessed in the first trimester. The trophoblast and angiogenesis
markers ADAM-12 (a disintegrin and metalloprotease 12), pregnancy-associated plasma protein-
A (PAPP-A), PP13, placental growth factor (PlGF), soluble fms-like tyrosine kinase-1, and
endoglin were measured in a case-control subset of 174 women with preeclampsia and 509
controls.
Results—Univariable analysis revealed maternal age, race, marital status, years of education,
source of medical payment, prenatal caregiver, body mass index (BMI), and systolic blood
pressure at enrollment were significantly associated with preeclampsia. Mean platelet volume was
greater at enrollment in women who later developed preeclampsia (median 9.4 vs 9.0fl, p=0.02).
First-trimester concentrations (multiples of the median) of ADAM-12 (1.14 vs 1.04, p=0.003),
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PAPP-A (0.94 vs 0.98, p=0.04), and PlGF (0.83 vs 1.04, p<0.001) were significantly different in
women who developed preeclampsia compared with controls. The optimal multivariable model
included African American race, systolic blood pressure, BMI, education level, ADAM-12,
PAPP-A and PlGF, and yielded an area under the curve of 0.73 (95% CI 0.69–0.77) and a
sensitivity of 46.1% (95% CI 38.3–54.0) for 80% specificity.
Conclusion—A multivariable analysis of clinical data and biochemical markers in the first
trimester did not identify a model that had clinical utility for predicting preeclampsia in a low-risk
nulliparous population.
Introduction
Preeclampsia is the leading cause of fetal growth restriction, indicated premature delivery,
and is responsible for over 50,000 maternal deaths annually worldwide (1–2). A screening
test that could identify women early in pregnancy who would later develop preeclampsia
would allow increased surveillance of those at risk, and reduce surveillance for those
unlikely to develop the syndrome. Identification of an at-risk population would foster
investigative studies and clinical trials.
Although defined by hypertension and proteinuria, preeclampsia involves multiple organ
systems (e.g. renal, liver, brain, vascular, coagulation, placenta) that may define different
pathophysiological phenotypes. Thus phenotype-specific (3) panels of biomarkers may be
necessary to identify those at risk prior to appearance of overt disease (hypertension and
proteinuria).
Here we describe an observational study in low-risk nulliparous women. Biomarkers chosen
are based on the potential different underlying pathophysiologies of preeclampsia. We
measured maternal blood concentrations of the syncytiotrophoblast proteins disintegrin and
metalloproteinase 12 (ADAM12) (4), that cleaves insulin-like growth factor-binding protein
(IGFBP) -3 and -4, pregnancy-associated plasma protein-A (PAPP-A) (5), which cleaves
IGFBP-4 (6) and may regulate trophoblast invasion, together with the galectin Placental
protein 13 (PP13) (7), a marker of trophoblast function. Preeclampsia is also associated with
altered expression of placental derived pro- and anti-angiogenic proteins placental growth
factor (PlGF), a vascular endothelial growth factor (VEGF) family member, soluble fms-like
tyrosine kinase-1 (sFlt-1), the soluble form of Flt-1 VEGF receptor, and soluble endoglin, a
transforming growth factor β (TGFβ) co-receptor. Disturbances in the coagulation system
are reported in preeclampsia, particularly decreased platelet number and increased platelet
volume (8–9), hence we performed a CBC including platelet parameters. The primary
objective was to identify clinical characteristics and biochemical markers in first-trimester
samples that would possibly predict the subsequent development of preeclampsia.
Methods
Study design
The Eunice Kennedy Shriver National Institute of Child Health and Human Development
(NICHD) Maternal-Fetal Medicine Units (MFMU) Network conducted this study as a
planned observational cohort of a previously reported larger randomized controlled trial to
estimate whether antioxidant supplementation (1000mg vitamin C and 400IU of vitamin E)
prevented preeclampsia in nulliparous women at low risk for developing the syndrome(10).
Women in the randomized clinical trial were eligible to participate in this cohort if their
gestational age at enrollment was between 9 weeks, 0 days and 12 weeks, 6 days. Written
informed consent was obtained from every participant and the study was approved by the
institutional review board at each clinical site and the data coordinating center.
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Clinical information including demographics, medical, obstetrical, family, social and sexual
history was obtained at the time of enrollment by personal interview and chart review.
Anthropometric measurements were taken for determination of body mass index and body
fat by the waist/hip ratio at enrollment. Four measures of blood pressure were assessed: 1)
systolic blood pressure, 2) diastolic blood pressure, 3) mean arterial pressure [diastolic +
1/3(systolic-diastolic)], and 4) pulse pressure (systolic-diastolic). A complete blood count
(CBC) was performed and additional blood collected and stored for future evaluation of
biochemical assays.
Biochemical assays
After enrollment but before study drug initiation blood was collected into EDTA and serum
tubes, plasma or serum separated, aliquoted and stored at −70°C until analysis. For the
biochemical marker analysis, a case-control study was performed: 174 women diagnosed
with preeclampsia and an approximately 3:1 random sample of 509 normotensive, non-
proteinuric women matched by center and gestational age at enrollment.
Three biomarkers, ADAM12, PAPP-A and PP-13, were measured in serum by NTD
Laboratories, (Huntington Station NY). ELISA kits were used with inter-assay coefficients
of variation of 7% at 146ng/ml, 4% at 2243mU/ml and 3% at 115pg/ml respectively. Three
biomarkers, sFlt-1, endoglin, and PlGF, were measured in EDTA plasma using Luminex
assays developed by Rules Based Medicine (Austin, TX). The inter-assay coefficients of
variation were 9% at 1.378ng/ml for sFlt-1, 8% at 3.91ng/ml for Endoglin, and 10% at
476pg/ml for PlGF.
Primary Outcome
The primary outcome was the development of preeclampsia including mild and severe
preeclampsia, HELLP syndrome and eclampsia. Mild preeclampsia was defined as mild
pregnancy-associated hypertension (140–159 systolic or 90–109 diastolic on 2 occasions, 2–
240 hours apart) and proteinuria (300–4,999 mg total protein/24 hours, 2+ or higher on
dipstick testing, or a protein-to-creatinine ratio of 0.35 or higher). Severe preeclampsia was
defined as preeclampsia with either severe pregnancy-associated hypertension (≥160 systolic
or ≥110 diastolic on 2 occasions, 2–240 hours apart, or a single occurrence treated with anti-
hypertensives) or protein excretion of 5g or more in a 24-hour urine sample or as mild
pregnancy-associated hypertension with oliguria (<500 ml), pulmonary edema, or
thrombocytopenia (platelet count of <100,000 per mm3). For this analysis, severe
preeclampsia, HELLP syndrome and eclampsia were combined as severe preeclampsia.
Early-onset preeclampsia was defined as the development of preeclampsia prior to 34
weeks’ gestation. Preeclampsia was confirmed through central review, using a standardized
protocol by 3 reviewers not associated with the clinical site of origin, of de-identified
medical records of all women with pregnancy-associated hypertension.
Statistical Analysis
For any given biomarker, the sample size of 683 with approximately 3:1 controls to cases
yields 95% power to detect an odds ratio of 2 if approximately 25% of the controls are
exposed (i.e. above the 75th percentile). This sample size also yields more than 80% power
to detect as little as a 0.25 standard deviation in difference between cases and controls when
treating a biomarker as a continuous variable.
Categorical variables were compared using the chi-square test and continuous variables
using the Wilcoxon rank-sum test. Multiples of the median (MoM) were computed for each
biomarker by dividing the observed measurement by the expected median which was
derived from multiple regression of gestational age at sample collection, maternal weight in
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kilograms, racial group, and smoking during pregnancy in the women that did not have an
elevated blood pressure, proteinuria or a small for gestational age infant. All variables that
were significant with a p-value less than 0.1 were included in the expected median model.
The 75th percentile cutoff was defined using the women that did not have an elevated blood
pressure, proteinuria or a small for gestational age infant.
Logistic regression analysis was used to determine which factors were significantly
associated with preeclampsia. The final model was selected using backward elimination in
which all variables were initially included in the model and then selectively removed if not
significant (p<0.10). The performance of screening for individual markers and the final
multivariable model was determined by receiver operating characteristics (ROC) curves and
calculating the sensitivity for a fixed 80% specificity. The specificity was set at 80% to
maintain a reasonable false positive rate.
Unless specifically noted, a nominal p value less than 0.05 was considered to indicate
statistical significance and no adjustments were made for multiple comparisons. Analyses
were performed using SAS software (Cary, NC).
Results
Figure 1 shows the enrollment and follow-up of the women who participated in the original
trial and the observational cohort in 16 clinical centers between April 2004 and February
2008. Of the 2,434 women enrolled into the observational cohort, 40 (1.6%) were lost to
follow-up, resulting in a final cohort of 2,394. The median gestational age at enrollment was
11.6 (range 8.7–13.9) weeks. The overall incidence of preeclampsia (7.4%) and was not
different between those allocated to antioxidants or to placebo (7.9% vs 6.8% respectively,
p=0.32). Data were available for 176 women who developed preeclampsia of whom 72
developed severe preeclampsia. Only 18 women developed early onset preeclampsia, a
number too small to do multivariable analysis.
Clinical characteristics
Clinical characteristics obtained at their first-trimester enrollment visit are reported in Table
1. Univariable analysis revealed that maternal age, race, marital status, years of education,
primary source of medical payment, prenatal caregiver, body mass index (BMI) and systolic
blood pressure at enrollment were significantly associated with the development of
preeclampsia (Table 1). These clinical characteristics were evaluated in a logistic regression
model to predict preeclampsia. Of the four measures of blood pressure evaluated, systolic
blood pressure was the most significant (p=0.001) and had the highest area under the curve
(AUC=0.58, 95% CI [0.53–0.62]). Backward elimination resulted in a final model that
included African American race (aOR; 95% CI; 1.7, 1.1–2.6), Hispanic race (1.5, 1.0–2.5),
systolic blood pressure (1.1, 1.1–1.2 per five unit increase) and BMI (1.1, 1.0–1.3 per five
unit increase) at enrollment, and education level (0.9, 0.9–1.0 per one unit increase). This
model had a sensitivity of 36% (95% CI 29–44) and specificity of 80% for development of
preeclampsia; the area under the curve was 0.65 (95% CI, 0.61–0.69). When development of
severe preeclampsia was considered, pulse pressure showed the most significant association
(AUC 0.60, 95% CI 0.53–0.66) of the four blood pressure measures. Prenatal caregiver,
infection, the use of prenatal vitamins, pulse pressure, years of education and number of sex
partners were found to be significantly associated with development of severe preeclampsia.
The final clinical model for prediction of severe preeclampsia yielded an AUC of 0.67, 95%
CI 0.61–0.74) with a sensitivity of 42% (95% CI 30–54) at 80% specificity.
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Mean platelet volume (MPV) was significantly higher in the first trimester in women who
later developed preeclampsia; however, there was no difference in white blood count, red
blood count, hemoglobin, hematocrit, and platelet count (Table 2). MPV differed among the
racial groups (Hispanic median 10.6fl [range 6.7–14.1], African American median 9.0fl
(range 6.3–14.0) and Caucasian median 8.6fl (range 6.4–13.4) respectively, p<0.001) and
was slightly higher with increasing BMI. The proportion of women with a MPV MoM at or
above the 75th percentile was higher among preeclamptics compared with normotensive,
non-proteinuric women (31.6% vs 24.3%, p=0.03). However, the area under the ROC curve
for MPV MoM as a continuous measure was 0.54 (95% CI 0.49–0.58) with a sensitivity of
25% (95% CI 19–32) for 80% specificity. MPV MoM was not found to be associated with
development of severe preeclampsia (p=0.68).
Biochemical markers
Biomarker concentrations were measured in 174 women who later developed preeclampsia
and 509 normotensive and non-proteinuric women. Comparison of first-trimester
concentrations (MoM) revealed that while ADAM-12 was significantly higher and PAPP-A
significantly lower, there was no difference for PP13 in those patients who went on to
develop preeclampsia compared with women who remained normotensive and non-
proteinuric (Table 3). The proportion of women with an ADAM-12 MoM at or above the
75th percentile was higher among preeclamptics compared with normotensive, non-
proteinuric women (35.5% vs 25.0%, p=0.009).
Among the angiogenic markers, PlGF were significantly lower in women who went on to
develop preeclampsia compared with women who remained normotensive and non-
proteinuric; however, sFlt and endoglin were not different (Table 3). PlGF had the highest
area under the curve (0.61) with a sensitivity of 32% (95% CI 25–39) for 80% specificity
(Table 3). The proportion of women with a PlGF MoM below the 25th percentile was higher
among preeclamptics compared with normotensive, non-proteinuric women (38.5% vs
25.0%, p<0.001).
When all six first trimester biomarkers were combined, the area under the curve increased to
0.66 (0.62–0.71). However this yielded a sensitivity of 38% (95% CI 31–46) for a fixed 80%
specificity.
When development of severe preeclampsia was considered, only ADAM-12, PAPP-A and
PlGF were found to be significantly different in the first trimester in those women who
developed severe preeclampsia (all p≤0.001) compared with normotensive women. When all
6 biomarkers were combined an AUC of 0.72 (95% CI 0.65–0.78) with a sensitivity of 48%
(95% CI 35–60) for a fixed 80% specificity for predicting severe preeclampsia was found.
Multivariable Model
Clinical and biochemical factors individually identified as significant predictors of
preeclampsia were initially included in the multivariable model. In combination, two factors
were no longer significant: Hispanic race and MPV MoM. The final predictive model that
included African American race, systolic blood pressure and BMI at enrollment, education
level, ADAM-12 MoM, PAPP-A MoM and PlGF MoM had an area under the curve of 0.73
(95% CI 0.69–0.77) with a sensitivity of 46% (95% CI 38–54) for 80% specificity (Table 4,
Figure 2). ADAM-12 MoM and PAPP-A MoM were highly correlated (r=0.46, p<0.001).
Removal of ADAM-12 MoM and PAPP-A individually from the final model resulted in a
slight decrease in the AUC (0.72 (0.67–0.76) for ADAM-12 and 0.72 (0.68–0.76) for PAPP-
Myatt et al. Page 5













A). The AUC when both biochemical markers were removed was 0.71 (0.67–0.76) with a
sensitivity of 46% (95% CI 38–54) for 80% specificity.
A final predictive model was also constructed for development of severe preeclampsia.
Variables remaining in the final model included clinical (obstetric caregiver and pulse
pressure) and biomarker (ADAM12, PAPPA and PlGF) data. This gave an AUC of 0.75
(95% CI 0.68–0.81) with a sensitivity of 55% (95% CI 43–67) at a fixed 80% specificity.
Discussion
This study was performed in a nulliparous population, with collection of a comprehensive
clinical data set and with a standardized definition of preeclampsia that allowed for a
rigorous evaluation. Despite evaluation of multiple first trimester clinical and biochemical
parameters, we were unable to identify an algorithm that could predict subsequent
preeclampsia with clinically useful sensitivity and specificity. When calculating sensitivity
with specificity set at 80% we correctly identified less than half of those women who
developed preeclampsia, i.e. less than the flip of a coin, and just more than half of those who
developed severe preeclampsia. The small number of patients with early onset preeclampsia
unfortunately precluded analysis for this group with a high incidence of maternal and fetal
morbidity.
Multivariable analysis demonstrated that African American or Hispanic race, systolic blood
pressure, BMI at enrollment, and education level were the strongest clinical predictors of
development of preeclampsia but with only 36% sensitivity at 80% specificity. In contrast to
previous findings diastolic blood pressure at enrollment (11) was not significantly higher.
Hispanic ethnicity is not traditionally recognized as a risk factor for preeclampsia but is
related to an increased incidence of obesity, metabolic syndrome and diabetes (12). Recent
reports utilizing clinical variables collected at less than 15 or 16 weeks gestation similarly
noted their low sensitivity for prediction of preeclampsia (13–14). When predicting severe
preeclampsia the multivariable analysis of clinical predictors was improved to a sensitivity
of 42% at 80% specificity, although still not clinically useful.
Preeclampsia is proposed to have an immune component with a protective effect of exposure
to paternal antigens (15–16) but we found no relationship between number of partners or the
duration of the sexual relationship and development of preeclampsia. Nor was there an
association of smoking, a family history of preeclampsia or cardiovascular disease and
development of the syndrome. This contrasts with the reports from Chesley (17) and more
recently that a positive family history was associated with a 20–30% risk of developing
preeclampsia (18). Our failure to find such associations may reflect our racially and
ethnically heterogeneous population with a smaller proportion of smokers (16.9%) and a
larger number of obese (22.5%) and overweight (26.0%) women.
Of the blood parameters only MPV, a sensitive indicator of platelet activation and
consumption (19) was different at enrollment, being modestly greater in those who
subsequently developed preeclampsia compared with those who remained normotensive.
MPV is higher in patients with hypertension and pre-hypertension (20), in insulin resistant,
non-obese, non-diabetic patients with coronary artery disease (21) and in those with diabetes
mellitus, hypertension, hypercholesterolemia, smoking and obesity, which are all reported
risk factors for preeclampsia. Cross-sectional studies of MPV in women with established
preeclampsia revealed high sensitivity and specificity (8). We found that MPV MoM was
significantly higher in the first trimester in women destined to develop preeclampsia
preceding the clinical onset by 16–18 weeks, but with poor sensitivity and specificity. MPV
MoM was however not significantly higher in women who later developed severe
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preeclampsia, suggesting platelet activation is not common to all cases of preeclampsia.
Unlike previous reports (22) the ratio of platelet volume/number did not relate to
development of preeclampsia (data not shown). The association of platelet volume with
African American and Hispanic race, first-trimester BMI and systolic blood pressure
indicates we may be identifying susceptible women with subclinical vascular dysfunction
(23).
Microarray analysis revealed ADAM12 to be the most highly upregulated gene transcript in
placental tissue (24) from women with established preeclampsia, with corresponding
increases in ADAM12 in maternal serum. Our finding of significantly increased serum
concentrations of ADAM12 in the first trimester contradicts reports of decreased ADAM12
(25–26) in women who subsequently developed preeclampsia. This may be due to differing
patient populations; however we agree with previous studies, that another proteinase, PAPP-
A, was significantly lower in the first trimester (27–28) in women who developed
preeclampsia compared with those who did not. Although significantly different at 9–12
weeks of gestation, the sensitivity, either singly or combined of ADAM12 or PAPPA, for
prediction of subsequent preeclampsia did not have clinical utility in agreement with
previous smaller studies (26).
In contrast to the reports that first trimester PP13 is significantly reduced (29–31) in those
patients who went on to develop preeclampsia we find no significant difference. A smaller
retrospective study reported similar negative findings for PP13 although it found, as we did,
a positive association for PAPP-A (32) Our finding of no increase in predictive power by
combined measurement of PP13 and PAPP-A again agrees with recent studies (33)–(34).
Significant changes in the ratio of pro-angiogenic (PlGF) to antiangiogenic (sFlt-1 and
endoglin) markers precede the clinical presentation of preeclampsia by several weeks (35).
PlGF has the best predictive power in the first trimester but with low sensitivity and
combination of angiogenic and antiangiogenic markers i.e. PlGF/sFlt and PlGF/endoglin
ratios did not appreciably increase the sensitivity (data not shown). The low predictive
capability of suites of trophoblast function or placental pro-angiogenic/antiangiogenic
markers indicates that either the involvement of these agents in the pathophysiology of
preeclampsia is a late event or that there are several pathologic phenotypes leading to the
syndrome of preeclampsia (3, 36).
The low sensitivity (46.1%) from this multivariable analysis of clinical risk factors and
biochemical markers points to the heterogeneity of preeclampsia, the difficulty of
identifying at-risk patients from among a low-risk group and of defining an enriched
population for study. When new biomarkers are advanced they may similarly lack sensitivity
if the syndrome has several pathologic phenotypes. Defining the clinical outcomes of
patients identified by abnormal biomarker values in the first trimester may prove useful in
elucidating if preeclampsia has several different underlying pathologies. Phenotyping and
predicting disease based on biomarkers may prove more useful for diagnosis of disease and
outcome in individuals rather than a clinical diagnosis of the preeclampsia syndrome.
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Enrollment and follow-up of study participants.
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Receiver operating characteristic curve for final predictive model. Clinical and biochemical
factors individually identified as significant predictors of preeclampsia (African American
race, systolic blood pressure and body mass index [BMI] at enrollment, education level, a
disintegrin and metalloprotease 12 [ADAM-12] multiple of the mean [MoM], pregnancy-
associated plasma protein-A [PAPP-A] MoM, and placental growth factor [PlGF] MoM)
were included in the final multivariable predictive model. This model had an area under the
curve of 0.73 (95% CI 0.69–0.77).
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Table 1
Clinical Characteristics Assessed at Enrollment
Characteristic Preeclampsia (n=176) No Preeclampsia (n=2,218) Relative Risk (95%
CI)
P
Maternal age 22 [19–25] 23 [20–26] -- 0.02
Race -- <0.001
 African American 61 (34.7) 531 (23.9) 2.0 (1.4–2.8)
 Hispanic 53 (30.1) 551 (24.8) 1.7 (1.2–2.4)
 Caucasian or other 62 (35.2) 1,136 (51.2) Referent
Married 62 (35.2) 1,034 (46.6) 0.6 (0.5–0.9) 0.004
Education (total years) 12 [11–14] 13 [12–16] <0.001
Private insurance 52 (29.5) 917 (41.3) 0.6 (0.5–0.8) 0.002
Prenatal care by obstetrician 77 (43.8) 1,272 (57.3) 0.6 (0.5–0.8) <0.001
Previous pregnancy 36 (20.5) 508 (22.9) 0.9 (0.6–1.2) 0.46
Family history of preeclampsia 26 (14.8) 294 (13.3) 1.1 (0.8–1.7) 0.57
Maternal family history cardiovascular disease 79 (44.9) 916 (41.3) 1.1 (0.9–1.5) 0.35
Maternal family history adult onset diabetes 81 (46.0) 948 (42.7) 1.1 (0.9–1.5) 0.40
Infections during pregnancy 33 (18.8) 347 (15.6) 1.2 (0.9–1.8) 0.28
Smoked during pregnancy 28 (15.9) 377 (17.0) 0.9 (0.6–1.4) 0.71
Alcohol during pregnancy 12 (6.8) 246 (11.1) 0.6 (0.3–1.1) 0.08
Multivitamins during pregnancy 131 (74.4) 1,768 (79.7) 0.8 (0.5–1.0) 0.10
Number of sex partners in lifetime 3 [1–5] 3 [1–5] -- 0.35
Duration of sexual relationship (months) 19 [9–42] 24 [10–45] -- 0.45
BMI at enrollment 27.3 [23.0–32.2] 24.6 [21.8–29.0] -- <0.001
Waist to hip ratio* 0.9 [0.8–0.9] 0.8 [0.8–0.9] -- 0.08
Blood pressure
 Systolic 112 [108–120] 110 [102–118] -- <0.001
 Diastolic 68 [60–72] 66 [60–70] -- 0.33
BMI, body mass index.
Data are n (percent) or median [interquartile range].
*
Data available on 2,325 women (171 preeclampsia, 2,154 no preeclampsia)
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Table 2
Complete Blood Count Measured in the First Trimester
Biomarker Preeclampsia (n=176) No Preeclampsia (n=2,218) P
White blood count (×103/mm3)* 8.4 [7.2–10.1] 8.4 [7.0–9.8] 0.59
Red blood count (×106/mm3)* 4.3 [4.1–4.5] 4.3 [4.0–4.5] 0.18
Hemoglobin (g/dl) † 12.7 [12.0–13.4] 12.8 [12.1–13.5] 0.11
Hematocrit (%)* 37.0 [35.0–39.0] 37.2 [35.4–39.2] 0.33
Platelet count (×103/mm3) ‡ 267 [227–303] 261 [229–302] 0.94
Mean platelet volume (fl) § 9.4 [8.2–11.0] 9.0 [8.1–10.4] 0.02
Data are median [interquartile range].
*
Data available on 2,348 women (173 preeclampsia, 2175 no preeclampsia)
†
 Data available on 2,349 women (173 preeclampsia, 2176 no preeclampsia)
‡
 Data available on 2,345 women (172 preeclampsia, 2173 no preeclampsia)
§
 Data available on 2,338 women (171 preeclampsia, 2167 no preeclampsia)
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Table 4
Final Multivariable Model for Preeclampsia
Predictor Odds Ratio 95% CI P
African American 1.53 1.00–2.35 0.051
Systolic blood pressure* 1.04 1.02–1.07 <0.001
Education level* 0.93 0.86–1.00 0.052
BMI at enrollment* 1.05 1.02–1.09 0.002
ADAM-12 MoM * 2.61 1.56–4.38 <0.001
PAPP-A MoM * 0.73 0.58–0.90 0.004
PlGF MoM * 0.52 0.34–0.79 0.002
BMI, body mass index; ADAM-12, a disintegrin and metalloprotease 12; MoM, multiples of the median; PAPP-A, pregnancy-associated plasma
protein-A; PlGF, placental growth factor.
*
Per one unit increase.
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